CD47 and neoplasm: Similar to PD‐L1, upregulation through EGFR activation either by EGF ligand or oncogenic mutations, CD47 could be overexpressed as a result of PI3K‐AKT and MEK‐ERK axes upper activation in NSCLC cells.28 To the best of our knowledge, this is the first study that reports tumor CD47 overexpression associated with the presence of EGFR activating mutations and its negative impact on survival of NSCLC patients.